Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
AbbVie today announced that the United States Food and Drug Administration (FDA) has approved expanding […]
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite
Lipella Pharmaceuticals, a clinical-stage biotechnology company addressing serious diseases with significant unmet need, has entered […]
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
Acadia Pharmaceuticals today announced that DAYBUE™ (trofinetide) is now available for the treatment of Rett […]
Otsuka and Lundbeck Issue Statement on FDA Advisory Committee Meeting on REXULTI® for the Treatment of Agitation Associated with Alzheimer’s Dementia
Otsuka Pharmaceutical and Lundbeck Pharmaceuticals announce the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee […]
Nerivio® Proven Effective in Real-World Setting as Drug-Free Acute Treatment of Migraine for Adolescents
Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain […]
Discovery Life Sciences Acquires ReachBio Research Labs
Discovery Life Sciences, the Biospecimen and Biomarker Specialists™, has acquired Seattle-based ReachBio Research Labs (ReachBio®), […]
FDA Grants Accelerated Approval for PADCEV® with KEYTRUDA for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
Seagen and Astellas Pharma have announced the United States Food and Drug Administration (FDA) has […]
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the FDA
Vertex Pharmaceuticals and CRISPR Therapeutics today announced the completion of the rolling Biologics License Applications […]
Orexo Shares New Timeline for the High-Dose Rescue Medication for Opioid Overdose, OX124
Orexo today announces the expected US launch of OX124, a high-dose rescue medication for opioid overdose, […]
Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa
Nanoscope Therapeutics, today announced topline results from the Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more